Dopamine D2/D3 Agonists with Potent Iron Chelation, Antioxidant and Neuroprotective Properties: Potential Implication in Symptomatic and Neuroprotective Treatment of Parkinson’s Disease
Authors:
- 12 May 2011
- journal article
- research article
- Published by Wiley in ChemMedChem
- Vol. 6 (6) , 991-995
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Novel D3 dopamine receptor‐preferring agonist D‐264: Evidence of neuroprotective property in Parkinson's disease animal models induced by 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine and lactacystinJournal of Neuroscience Research, 2010
- Genetic or Pharmacological Iron Chelation Prevents MPTP-Induced Neurotoxicity In VivoNeuron, 2003
- Lack of up‐regulation of ferritin is associated with sustained iron regulatory protein‐1 binding activity in the substantia nigra of patients with Parkinson's diseaseJournal of Neurochemistry, 2002
- Ironing out Parkinson's disease: is therapeutic treatment with iron chelators a real possibility?Aging Cell, 2002
- Dopamine-dependent neurotoxicity of α-synuclein: A mechanism for selective neurodegeneration in Parkinson diseaseNature Medicine, 2002
- Book Review: Iron and Parkinson’s DiseaseThe Neuroscientist, 2002
- Brain iron pathways and their relevance to Parkinson's diseaseJournal of Neurochemistry, 2001
- The A53T α-Synuclein Mutation Increases Iron-Dependent Aggregation and ToxicityJournal of Neuroscience, 2000
- "ON-OFF" EFFECTS IN PATIENTS WITH PARKINSON'S DISEASE ON CHRONIC LEVODOPA THERAPYThe Lancet, 1976
- 6-hydroxy-dopamine induced degeneration of central monoamine neuronsEuropean Journal of Pharmacology, 1968